Literature DB >> 1768667

Visual development in the blepharophimosis syndrome.

M Beaconsfield1, J W Walker, J R Collin.   

Abstract

One hundred and one cases of the blepharophimosis syndrome presenting over a decade are reviewed with particular attention to the factors influencing their visual development. Three distinct clinical patterns emerge--severe bilateral ptosis, moderate bilateral ptosis, and asymmetric ptosis--and their differing incidence of amblyopia and strabismus is discussed. The risk of amblyopia is much higher than previously believed (56.4% in our series) and preventive management is discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1768667      PMCID: PMC1042558          DOI: 10.1136/bjo.75.12.746

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  5 in total

1.  Operations for epicanthus and blepharophimosis; an evaluation and a method for shortening the medial canthal ligament.

Authors:  C C JOHNSON
Journal:  Am J Ophthalmol       Date:  1956-01       Impact factor: 5.258

2.  Further considerations on the surgical correction of blepharophimosis (epicanthus).

Authors:  E B SPAETH
Journal:  Am J Ophthalmol       Date:  1956-01       Impact factor: 5.258

3.  Blepharophimosis and its association with female infertility.

Authors:  C A Jones; J R Collin
Journal:  Br J Ophthalmol       Date:  1984-08       Impact factor: 4.638

4.  Congenital eyelid anomalies in children.

Authors:  J S Crawford
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1984 Jul-Aug       Impact factor: 1.402

5.  Uses of fascia in ophthalmology and the benefits of autogenous sources.

Authors:  J S Crawford; T W Doucet
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1982 Jul-Aug       Impact factor: 1.402

  5 in total
  11 in total

1.  Mersilene mesh brow suspension: efficiency and complications.

Authors:  C R Hintschich; M Zürcher; J R Collin
Journal:  Br J Ophthalmol       Date:  1995-04       Impact factor: 4.638

2.  Linkage analysis in blepharophimosis-ptosis syndrome confirms localisation to 3q21-24.

Authors:  H S Harrar; S Jeffery; M A Patton
Journal:  J Med Genet       Date:  1995-10       Impact factor: 6.318

3.  Amblyopia in childhood eyelid ptosis.

Authors:  Gregory J Griepentrog; Nancy Diehl; Brian G Mohney
Journal:  Am J Ophthalmol       Date:  2013-02-18       Impact factor: 5.258

4.  [Blepharophimosis syndrome: a special form of congenital ptosis].

Authors:  Hanan Handor; Zouheir Hafidi; Mina Laghmari; Ihsane Sabrane; Olive Rosine Mastanga; Rajae Daoudi
Journal:  Pan Afr Med J       Date:  2015-03-23

5.  Nasolacrimal duct obstruction: Does it really increase the risk of amblyopia in children?

Authors:  V Akila Ramkumar; Sumita Agarkar; Bipasha Mukherjee
Journal:  Indian J Ophthalmol       Date:  2016-07       Impact factor: 1.848

6.  Factors related to amblyopia in congenital ptosis after frontalis sling surgery.

Authors:  Youn-Shen Bee; Pei-Jhen Tsai; Muh-Chiou Lin; Ming-Ying Chu
Journal:  BMC Ophthalmol       Date:  2018-11-21       Impact factor: 2.209

7.  Amblyopia risk factors in congenital nasolacrimal duct obstruction: A longitudinal case-control study.

Authors:  YungJu Yoo; Hee Kyung Yang; Namju Kim; Ho-Kyoung Choung; Jeong-Min Hwang; Sang-In Khwarg
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

8.  Single stage surgery for Blepharophimosis syndrome.

Authors:  Kasturi Bhattacharjee; Harsha Bhattacharjee; Ganesh Kuri; Zeenat Tajmin Shah; Nilutparna Deori
Journal:  Indian J Ophthalmol       Date:  2012 May-Jun       Impact factor: 1.848

9.  Can single stage surgery in Blepharophimosis syndrome be practiced universally?

Authors:  Ruchi Goel; Amit Goel
Journal:  Indian J Ophthalmol       Date:  2013-07       Impact factor: 1.848

Review 10.  The Genetic and Clinical Features of FOXL2-Related Blepharophimosis, Ptosis and Epicanthus Inversus Syndrome.

Authors:  Cécile Méjécase; Chandni Nigam; Mariya Moosajee; John C Bladen
Journal:  Genes (Basel)       Date:  2021-03-04       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.